Lupin Q1 Review: Dolat Capital Maintains 'Add', But Cuts Target Price — Here's Why
Timely launches of injectables and inhalation products will be further triggers to the brokerage's earnings estimates.
Lupin’s Q1 FY26 sales were slightly below estimates. Ebitda margin was above estimate due to higher gross margin led by Tolvaptan exclusivity and stable active pharma ingredient cost. Net profit came above estimate due to higher other income, forex gain and lower tax rate.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
We maintain our ‘Accumulate’ rating on Lupin Ltd. with a revised target price of Rs 2,162, valuing at 28x FY27E P/E. Timely launches of injectables and inhalation products will be further triggers to our earnings estimates.
Key risks:
US price erosion, higher competition in key products and escalation of compliance issues at Taradeep/ Mandideep Unit-I plants.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
